https://fortune.com/europe/2024/03/28/ozempic-maker-novo-nordisk-facing-pressure-as-study-finds-1000-appetite-suppressant-can-be-made-for-just-5/ * Europe * Energy * Economy * Tech * Retail * Lifestyle Home Page Already have an account?SIGN IN SEARCHSubscribe Now * Sections + FORTUNE 500 + News + Europe + Asia + Tech o AI + Finance o Personal Finance o Real Estate o Crypto + Leadership o Success + Well o Life o Health o Mind o Family o Aging Well + Recommends o Credit Cards # Best Airline Credit Cards # Best Balance Transfer Credit Cards # Best Business Credit Cards # Best Cash Back Credit Cards # Best Secured Credit Cards # Best Travel Credit Cards # Best 0% APR Credit Cards o Banking # Best Savings Accounts # Best High-Yield Savings Accounts # Best CD Rates # Best Money Market Accounts # Savings Calculator o Insurance o Mortgages o Investing o Loans o Health + Coupons + Education + Video * Rankings + FORTUNE 500 + GLOBAL 500 + MOST POWERFUL WOMEN + GREAT PLACE TO WORK LISTS + BEST MBA PROGRAMS + MORE RANKINGS * Analytics * Newsletters * Magazine + December 2023/January 2024 + October/November 2023 + August/September 2023 + June/July 2023 + April/May 2023 + February/March 2023 * Live Media * CEO Initiative Health *obesity Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5 BYMadison Muller, Robert Langreth and Bloomberg * * * * [GettyImage][GettyImage] CEO of Novo Nordisk Lars Fruergaard Jorgensen. Ludovic Marin--POOL/AFP/Getty Images Ozempic could be profitably produced for less than $5 a month even as maker Novo Nordisk A/S charges almost $1,000 in the US, according to a study that revives questions about prices for top-selling treatments for diabetes and obesity. The blockbuster drug could be manufactured for 89 cents to $4.73 for a month's supply, figures that include a profit margin, researchers at Yale University, King's College Hospital in London and the nonprofit Doctors Without Borders reported in the journal JAMA Network Open. That compares to the monthly US list price of $968.52 for Ozempic, a weekly injection. Novo declined to provide production costs for Ozempic and Wegovy, its related drug for obesity. The company said it's making significant investments to ensure that the public has access to its widely popular drugs. It's making about $6 billion in capital expenditures and spending $11 billion to acquire production facilities from Catalent Inc. as part of those efforts, according to an emailed response to questions. "This outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system," Senator Bernie Sanders, who has held hearings about high US drug prices, said in a statement after the findings came out. The Vermont independent called on Novo Nordisk to lower the list price of Ozempic to $155 a month or less, in line with what it charges in other countries. The study extends research showing how steep US markups are for GLP-1 drugs like Ozempic and Wegovy and underlines longstanding criticism of prices for diabetes therapies, especially insulin. On a per-month basis, Ozempic generally can be produced for less than various forms of insulin, a lifesaving diabetes drug that's been available for decades, the study found. "The profit margin is immense," on drugs like Ozempic, said Melissa Barber, a public health economist at Yale and the study's corresponding author. "There should be a conversation in policy about what is a fair price." Novo's combined 2023 sales of Ozempic and Wegovy topped $18 billion. Patents linked to the drugs are likely to expire in June 2033, according to estimates from Bloomberg Law. Novo shares fell 0.8% in Copenhagen, and have gained 26% this year. Transparency Goal Drug production costs are often shrouded in secrecy with little clarity on how they relate to prices, if at all. Barber and her colleagues used updated estimates for raw ingredient costs and focused on the costs of producing diabetes drugs, including GLP-1 drugs like Ozempic, along with other diabetes pills and insulins. "The goal of this research is to have receipts, to be as transparent as possible," Barber said. Novo and other drugmakers slashed US prices for some forms of insulin by as much as 75% last year under pressure from the Biden administration. By some estimates, however, the reductions made those products more profitable because they eliminated rebates paid to pharmacy benefit managers, the middlemen who negotiate prices for payers and employers. Novo said in an email that 75% of its gross earnings goes to rebates and discounts to ensure patients have access to products like semaglutide, the active ingredient in Wegovy and Ozempic. Drugmakers often cite the high costs of research that may last years as a reason for their prices. Spending on drug research and development was almost $5 billion last year and will rise this year, Novo said. Still, debate over the cost of drugs like Ozempic and Wegovy is ramping up. State health plans and Medicaid offices are seeing growing bills for Ozempic and its sister drug Wegovy, raising questions about whether the increases in cost are sustainable. In January, North Carolina cut off coverage of anti-obesity medicines for state employees, citing soaring costs and lack of agreement on pricing from drugmakers. Surprisingly, the study found that the biggest cost in producing Ozempic is not the active medicine, called semaglutide, but the disposable pens used to inject it. They can be made for no more than $2.83 per month's supply, the authors concluded, based on interviews with former employees and consultants to injection device manufacturers. One Ozempic pen is used weekly and lasts a month. Other Costs By contrast, the active drug in Ozempic can be produced for about 29 cents for a month's supply, or 7.2 cents for a typical weekly dose, the research found. It's not cheap to make -- semaglutide costs over $70,000 per kilogram. But only a tiny quantity of the drug is used in each weekly dose. Other costs include those of filling each pen, estimated at 20 cents per monthly dose, and other chemical ingredients, which the study estimates at 15 cents per monthly dose. The analysis doesn't include estimates for the cost of making Wegovy. Separate research from the University of Liverpool and elsewhere found last year that Wegovy could be produced for a mere $40 a month. Subscribe to the new Fortune CEO Weekly Europe newsletter to get corner office insights on the biggest business stories in Europe. Sign up for free. Latest in Health * 0 minutes ago * [yH5BAEAAAA][GettyImage] Health - obesity Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5 BYMadison Muller, Robert Langreth, and others * 0 minutes ago * Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk Leadership - stress Ozempic maker Novo Nordisk has a new goal for its leadership team: Make sure no more than 10% of your staff are stressed BYOrianna Rosa Royle * 0 minutes ago * [yH5BAEAAAA][GettyImage] Health - A.I. The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project BYChris Morris and Prarthana Prakash * 0 minutes ago * [yH5BAEAAAA][GettyImage] Commentary - careers Finland passed its flexible work act in 1996-and it may partly explain why it's the happiest nation BYMiika Makitalo * 0 minutes ago * A person using OzempicA person using Ozempic Retail - Novo Nordisk Wegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake 'skinny jabs', leading to surge in hospitalizations BYAshleigh Furlong and Bloomberg * 0 minutes ago * Bill Anderson, chief executive officer of Bayer AG, at the Berlin Global Dialogue in Berlin, Germany.Bill Anderson, chief executive officer of Bayer AG, at the Berlin Global Dialogue in Berlin, Germany. Health - Pharmaceutical Industry Bayer CEO compares the state of troubled pharma group to the time he fractured his leg skateboarding: 'We're badly broken in 4 places' BYRyan Hogg Most Popular * 0 minutes ago * [yH5BAEAAAA][GettyImage] Health Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5 BYMadison Muller, Robert Langreth, and others * 0 minutes ago * [yH5BAEAAAA][GettyImage] Finance A woman purchased a vacant Hawaiian lot for about $22,000. She was surprised to see a $500,000 home was built on it by mistake BYThe Associated Press * 0 minutes ago * [yH5BAEAAAA][AP24088374] Finance Home Depot's largest acquisition ever is an $18.25 billion bet on the housing market's severe shortage of new homes BYMichelle Chapman and The Associated Press * 0 minutes ago * [yH5BAEAAAA][GettyImage] Commentary The U.S. and its allies want to bring the entire chip supply chain in-house--and that could create an OPEC-style cartel for the digital age BYJaemin Lee * 0 minutes ago * [yH5BAEAAAA][GettyImage] Finance For New Yorkers, 'there are no consequences for not paying your property taxes' as delinquencies spike to $880 million BYMartin Z. Braun and Bloomberg * 0 minutes ago * [yH5BAEAAAA][GettyImage] Life Do turmeric supplements really treat pain, boost mood, and improve allergies? Experts say they work best for 2 conditions BYStephanie Watson Rankings * 100 Best Companies * Fortune 500 * Global 500 * Fortune 500 Europe * Most Powerful Women * Future 50 * World's Most Admired Companies * See All Rankings Sections * Finance * Leadership * Success * Tech * Asia * Europe * Environment * Fortune Crypto * Health * Well * Retail * Lifestyle * Politics * Newsletters * Magazine * Features * Commentary * MPW * CEO Initiative * Conferences * Personal Finance * Recommends * Coupons Customer Support * Frequently Asked Questions * Customer Service Portal * Privacy Policy * Terms of Use * Single Issues for Purchase * International Print Commercial Services * Fortune Brand Studio * Fortune Analytics * Fortune Conferences * Advertising * Business Development About Us * About Us * Editorial Calendar * Press Center * Work at Fortune * Diversity and Inclusion * Behavioral Advertising Notice * Terms and Conditions * Site Map (c) 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information | Ad Choices FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions. * * * * *